CA-ARIBIO
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities20.1.2026 14:30:00 CET | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory has achieved College of American Pathologists (CAP) accreditation. This milestone builds on the site’s Clinical Laboratory Improvement Amendments (CLIA) certification, obtained in July 2025, further strengthening its ability to deliver clinical-grade biomarker testing to support regulated drug development programs. CAP accreditation is recognized as a leading benchmark for laboratory quality, reflecting rigorous standards for operational excellence, technical competence, and quality oversight. Together with CLIA certification—regulated by the U.S. Centers for Medicare & Medicaid Services—these credentials confirm the San Diego laboratory’s compliance with federal requirements for clinical testing on human specimens and its readiness to support biomarker analyses aligned with clinical trial and regulatory expectations. “Achieving CAP accreditatio
Leon and SkyAccess Announce Official Integration to Automate Empty Leg Listings for Charter Operators Across Europe20.1.2026 14:24:00 CET | Press release
SkyAccess, a real-time empty leg flight marketplace that aggregates private jet repositioning flights from a network of certified operators, and Leon Software, a cloud-based aviation management software platform used by charter operators worldwide, today announced an official integration that enables Leon charter operators to automatically list eligible empty leg and repositioning flights on the SkyAccess empty-leg marketplace. Meeting Growing Demand for Empty Leg Flights in Europe The announcement comes as interest in empty leg flights continues to grow across Europe, particularly on short-haul routes between major business and leisure hubs. Travelers are increasingly seeking flexible, one-way private jet options and more transparent access to repositioning flights. “Empty legs move quickly, and speed matters,” said Paweł Szmagaj, CTO of Leon Software. “With the Leon Software–SkyAccess integration, operators can share up-to-date availability with the market faster, while maintaining f
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health20.1.2026 14:00:00 CET | Press release
Multi-year funding will advance oral health, as oral diseases are among the most prevalent and overlooked noncommunicable diseases impacting 3.7 billion people globally.1 Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/ “At Colgate-Palmolive, w
FGS Global Launches AI Advisory Practice and Acquires Threat Intelligence Firm Memetica20.1.2026 14:00:00 CET | Press release
Dedicated global practice to help organizations navigate and optimize AI comms transformationAI-driven threat intelligence offer identifies, assesses and mitigates emerging risks across the dark web FGS Global, the world's leading stakeholder strategy firm, today announced the launch of its AI Advisory practice and the acquisition of Memetica, a specialist technology consultancy in AI-driven threat detection and mitigation across social, dark web and fringe platforms. The new practice sits within FGS Global's recently formed AI and Innovation group led by Aaron Kwittken, Global Head of AI and Innovation. The AI Advisory practice builds on and consolidates FGS Global's deliberate, years-long investment in AI capabilities to support surging client demand for strategic and practical guidance on leveraging AI and emerging technologies to enhance communications efficacy, reputational defense and operational efficiencies. This critical work is supported by a global team of more than 200 stra
KnowBe4 Honored for Global Employee Experience Across Multiple Workplace Awards20.1.2026 14:00:00 CET | Press release
Recognized across 11 countries with certifications from Great Place to Work®, Computerworld, Top Workplaces, and America's Most Loved Workplaces® KnowBe4, the world-renowned platform that comprehensively addresses human and agentic AI risk management, today announced it has earned several prestigious workplace awards in Q4 2025. These include Great Place to Work® Certifications across 11 countries, recognition on Computerworld's 2026 Best Places to Work in IT list, and honors from Top Workplaces and America's Most Loved Workplaces®. The awards recognize KnowBe4's ongoing commitment to fostering an exceptional workplace culture that empowers employees to thrive both professionally and personally. "This recognition belongs to every single member of our KnowBe4 team," said Ani Banerjee, chief human resources officer at KnowBe4. "These awards validate our commitment to creating a workplace where people truly want to come to work each day. When employees feel valued and empowered, remarkabl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom